title: Response to "erlotinib and gastric Acid-reducing agents: a combination to avoid or to support?".
authors.affiliation: Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
authors.forename: S C
authors.initials: SC
authors.lastname: Lee
authors.affiliation: Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
authors.forename: H
authors.initials: H
authors.lastname: Zhao
authors.affiliation: 1] Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA [2] Oak Ridge Institute for Science and Education, Oak Ridge, Tennessee, USA.
authors.forename: F
authors.initials: F
authors.lastname: Wu
authors.affiliation: Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
authors.forename: L
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000818:Animals; D015195:Drug Design; D055808:Drug Discovery / Q000639:trends*; D004347:Drug Interactions / Q000502:physiology*; D004348:Drug Labeling / Q000639:trends*; D006801:Humans; D004364:Pharmaceutical Preparations / Q000378:metabolism*
chemical_list: D004364:Pharmaceutical Preparations